Article
Prograf produces more benefits for CYP3A5 low expression patients in early stage after kidney transplantation.
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie - 1 Apr 2017
Fan Bohan, Qiu Kui, Jiang Yihang, Hu Xiaopeng, Yin Hang, Wang Wei, Ren Liang, Liu Hang, Wang Wei, Zhang Xiaodong
Abstract excerpt
OBJECTIVE: This study is to analyze concentration changes of the prolonged-release and shorter-acting formulation of tacrolimus in patients with different CYP3A5 genotypes after kidney transplantation. METHODS: A single-factor retrospective analysis was performed in patients underwent allogeneic kidney transplantation with postoperative administration of Advagraf or Prograf in our hospital from May 2013 to June...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
